Shopping Cart
- Remove All
Your shopping cart is currently empty
Mozavaptan
🥰Excellent
Catalog No. T6288Cas No. 137975-06-5
Alias OPC31260l, OPC-31260
Mozavaptan (OPC-31260) is a competitive antagonist of vasopressin receptors, targeting both V1 and V2 receptors, with IC50 values of 1.2 μM and 14 nM, respectively.
Mozavaptan
🥰Excellent
Purity: 99.12%
Catalog No. T6288Alias OPC31260l, OPC-31260Cas No. 137975-06-5
Mozavaptan (OPC-31260) is a competitive antagonist of vasopressin receptors, targeting both V1 and V2 receptors, with IC50 values of 1.2 μM and 14 nM, respectively.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 10 mg | $43 | In Stock | |
| 25 mg | $68 | In Stock | |
| 50 mg | $98 | In Stock | |
| 100 mg | $156 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $30 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Mozavaptan"
Tolvaptan
OPC-41061
T2326150683-30-0
Tolvaptan (OPC-41061) is an orally bioavailable, selective, arginine vasopressin receptor 2 (V2, AVPR2) antagonist that can be used to treat hyponatremia.
- $32
Size
QTY
Nelivaptan
SSR149415, SR-149415, SR 149415
T28153439687-69-1In house
Nelivaptan (SR 149415) is a vasopressin V1b receptor antagonist that can eliminate CHS-induced GE damage and inhibit [3H]AVP binding in a competitive manner.
- $71
Size
QTY
Fuscoside
OPC 21268
T4355131631-89-5
Fuscoside (OPC-21268) is a non-peptide arginine vasopressin (AVP) receptor VI antagonist with an IC50 value of 0.4 μM[2].
- $52
Size
QTY
OPC-51803
SOU-003, SOU003, SOU 003, OPC51803, OPC 51803
T28257192514-54-8In house
OPC-51803 is an orally available nonapeptidylpressor (AVP) V(2) receptor selective agonist for the treatment of urinary incontinence and nocturia.
- $350
Size
QTY
E-4177
E4177, E 4177
T27229135070-05-2In house
E-4177 is an angiotensin II type 1 receptor (AT1R) antagonist and can be used to study cardiovascular diseases.
- $293
Size
QTY
Felypressin acetate
PLV2. H-Cys-Phe-Phe-Gln-Asn-Cys-Pro-Lys-Gly-NH2 (Disulfide bond), PLV-2, PLV 2, 2-(L-Phenylalanine)-8-L-lysinevasopressin
T2568L914453-97-7
Felypressin acetate (PLV-2) is an agonist of vasopressin 1 and acts on all arginine vasopressin receptors 1AS. Felypressin acetate can be used in dental procedures.
- $39
Size
QTY
Atosiban acetate
RWJ22164, RW22164, Atosiban acetate (90779-69-4 free base)
T5148914453-95-5
Atosiban acetate (RW22164) is an inhibitor of the hormones oxytocin and vasopressin. It is used as an intravenous medication as a labour repressant (tocolytic) to halt premature labor. Atosiban acetate (RW22164) inhibits the oxytocin-mediated release of inositol trisphosphate from the myometrial cell membrane. As a result, there is reduced release of intracellular, stored calcium from the sarcoplasmic reticulum of myometrial cells, and reduced influx of Ca2+ from the extracellular space through voltage gated channels. In addition, Atosiban acetate (RW22164) suppresses oxytocin-mediated release of PGE and PGF from the decidua. In human pre-term labor, atosiban, at the recommended dosage, antagonizes uterine contractions and induces uterine quiescence. The onset of uterus relaxation following atosiban is rapid, uterine contractions being significantly reduced within 10 minutes to achieve stable uterine quiescence.
- $67
Size
QTY
Terlipressin Acetate
Terlipressin acetate anhydrous
T13920L1884420-36-3
Terlipressin Acetate, a highly selective vasopressin V1 receptor agonist, on oxygen and glucose deprivation/re-oxygenation (OGD/R)-induced damage in intestinal epithelial cells (IEC-6).Terlipressin acetate exerts anti-inflammatory and anti-oxidative effects. Terlipressin acetate has the potential for hepatorenal syndrome and norepinephrine-resistant septic shock research.
- $41
Size
QTY
TASP0390325
TASP-0390325, TASP 0390325
T289261642187-96-9
TASP0390325 is an orally active and high affinity arginine pressin receptor 1B (V1B receptor) antagonist that shows antidepressant and anxiolytic activity in animal studies and blocks V1B receptors in the anterior pituitary gland in vivo.
- $52
Size
QTY
Conopressin S acetate(111317-90-9 free base)
Con-S acetate
TP1192L
Conopressin S acetate(111317-90-9 free base) (Con-S acetate) is a natural product isolated from Conus striatus, shows high affinity with vasopressin V1b receptor (AVPR1B), with a Ki of 8.3 nM.
- $50
Size
QTY
Balovaptan
RG7314
T144941228088-30-9
Balovaptan (RG7314) is a highly potent and selective brain-penetrant vasopressin 1a (hV1a) receptor antagonist, with Kis of 1 and 39 nM for human (hV1a) and mouse (mV1a) receptors. It is used for the research of autism.
- $60
Size
QTY
d[Cha4]-AVP acetate(500170-27-4 free base)
TP2082L
d[Cha4]-AVP acetate is a potent and selective human vasopressin V1B receptor agonist (Ki values are 1.2, 151, 240 and 750 nM for V1B, V1A, Oxytocin and V2 receptors respectively). Stimulates ACTH and corticosterone secretion and exhibits negligible vasopr
- $100
Size
QTY
Select Batch
Purity:99.12%
Contact us for more batch information
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.Product Introduction
Bioactivity
Chemical Properties
| Description | Mozavaptan (OPC-31260) is a competitive antagonist of vasopressin receptors, targeting both V1 and V2 receptors, with IC50 values of 1.2 μM and 14 nM, respectively. |
| Targets&IC50 | Vasopressin receptor 1:1.2 μM, V2 receptor:14 nM |
| In vitro | Mozavaptan (OPC-31260) is a nonpeptide, orally effective competitive inhibitor of AVP with a V2:V1 receptor selectivity ratio of 25:1 indicating relative V2 receptor selectivity. [1] Mozavaptan (OPC-31260) inhibits AVP binding to V1 and V2 receptors in a competitive manner. [2] |
| In vivo | Mozavaptan (OPC-31260) inhibits the antidiuretic action of exogenously administered AVP in water-loaded, alcohol-anaesthetized rats in a dose-dependent manner. OPC-31260 dose-dependently increases urine flow and decreased urine osmolality after oral administration at doses of 1 to 30 mg/kg in normal conscious rats. [2] |
| Kinase Assay | To determine binding kinetic constants, liver or kidney plasma membranes are incubated with increasing concentrations of [3H]-AVP with or without excess (1 μM) unlabelled AVP to obtain a saturation curve. To investigate whether mozavaptan interacts competitively or noncompetitively, the saturation binding of [3H]-AVP is examined in the absence and presence of mozavaptan at concentrations of 0.3 μM and 1 μM in liver membranes and 3 nM, and 10 nM in kidney membranes. Data on the saturation curve are plotted according to the method of Scatchard and fitted by a regression analysis[1]. |
| Alias | OPC31260l, OPC-31260 |
| Molecular Weight | 427.54 |
| Formula | C27H29N3O2 |
| Cas No. | 137975-06-5 |
| Smiles | CN(C)C1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12 |
| Relative Density. | 1.21 g/cm3 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 22.5 mg/mL (52.63 mM)  | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Mozavaptan | purchase Mozavaptan | Mozavaptan cost | order Mozavaptan | Mozavaptan chemical structure | Mozavaptan in vivo | Mozavaptan in vitro | Mozavaptan formula | Mozavaptan molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.